Drugs / EP2101
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00054912 | Feb 2003 → ? | colonic neoplasm | Epimmune | Completed | No outcome recorded |
| Phase 1 | NCT00054899 | Jan 2003 → ? | non-small cell lung carcinoma | Epimmune | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00104780 | Dec 2004 → ? | lung cancer | Epimmune | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EP2101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00054912 ↗ |
| Modality | Vaccine | “EP2101 is a new cancer vaccine containing 10 different peptide antigens.” NCT00054899 ↗ |
| Route | Subcutaneous | “EP-2101 emulsified in montanide ISA-51 subcutaneously” NCT00104780 ↗ |